Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 13Terminated 1Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 63Lymphoid 38Other hematologic neoplasm 20Thoracic 8Gastrointestinal 6Dermatologic 6Myeloid 4Genitourinary 4Other solid neoplasm 3Classical hematology 2CNS 2Breast 2Tumor-Agnostic 1Sarcoma 1Head & Neck 1Gynecologic 1Endocrine 1

Conditions

Oligodendroglioma 1Gliosarcoma 1Glioblastoma 1Brain Neoplasms 1Astrocytoma 1

Interventions

Cyclophosphamide 26Temozolomide 23Doxorubicin 22Radiotherapy 21Filgrastim 19Ifosfamide 15pazopanib 14Gemcitabine 14Etoposide 13Bevacizumab 13Irinotecan 12Cisplatin 12Magnetic Resonance Spectroscopy 11Imatinib Mesylate 11Granulocyte Colony-Stimulating Factor 11Carboplatin 11Radiation 9Methotrexate 9pembrolizumab 8fludarabine phosphate 8Rituximab 8Paclitaxel 8Docetaxel 8Cyclosporine 8Busulfan 8Antilymphocyte Serum 8fludarabine 7Vincristine 7Radiotherapy, Intensity-Modulated 7Mycophenolic Acid 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Bortezomib × Sarcoma × Clear all
NCT00006773 2013-01-24

Bortezomib in Treating Patients With Recurrent Glioma

National Cancer Institute (NCI)

Phase 1 Terminated
42 enrolled
CNSSarcoma

Astrocytoma, Brain Neoplasms, Glioblastoma, Oligodendroglioma, Gliosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡